Spectrum Pharmaceuticals, Inc.
157 Technology Drive
Irvine
California
92618
United States
Tel: 949-788-6700
Fax: 949-788-6706
Website: http://www.spectrumpharm.com/
Email: info@spectrumpharm.com
616 articles about Spectrum Pharmaceuticals, Inc.
-
Spectrum Pharmaceuticals Announces Submission to the U.S. Food and Drug Administration of Updated Biologics License Application for ROLONTIS®
10/24/2019
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with a primary focus in hematology and oncology, announced today that the company submitted an updated Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ROLONTIS (eflapegrastim).
-
Spectrum Pharmaceuticals Announces Publication of Positive Poziotinib Data in Cancer Cell
10/4/2019
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today a publication from The University of Texas, MD Anderson Cancer Center entitled, “Pan-Cancer Landscape and Functional Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
-
Spectrum Pharmaceuticals to Present Corporate Update at the 2019 Cantor Global Healthcare Conference on October 2nd
9/25/2019
Spectrum Pharmaceuticals announced that an overview of the company's business strategy and development-stage programs will be given at the 2019 Cantor Global Healthcare Conference being held in New York.
-
Spectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung Cancer
9/6/2019
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and beyond
-
Spectrum Pharmaceuticals to Present at Two Upcoming Investor Conferences in September 2019
9/3/2019
Spectrum Pharmaceuticals announced that an overview of the company's business strategy and development-stage programs will be given at two upcoming conferences being held in New York on September 10th and September 11th.
-
Spectrum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Pipeline Update
8/8/2019
Financial results for the three-month period ended June 30, 2019.
-
Spectrum Pharmaceuticals Announces Second Quarter 2019 Financial Results Conference Call
8/1/2019
Spectrum Pharmaceuticals, announced it will host a conference call with management to discuss the second quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, August 8, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
-
Spectrum Announces Expansion of the Poziotinib Clinical Program
7/22/2019
Spectrum Pharmaceuticals, Inc., announced that it is further expanding its poziotinib clinical program by adding three new cohorts in its cornerstone poziotinib clinical trial, ZENITH20.
-
BioSpace Movers and Shakers, June 21
6/21/2019
Biotech and pharma companies strengthen their leadership teams and committees with new appointments. -
Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors
6/20/2019
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced the appointment of Elizabeth Czerepak to the Board of Directors.
-
Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting
6/2/2019
Spectrum Pharmaceuticals, Inc. announced integrated analysis results from two Phase 3 clinical trials of ROLONTIS.
-
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 Global Healthcare Conference on June 5th
5/29/2019
Spectrum Pharmaceuticals announced that an overview of the company's business strategy and development-stage programs will be given at the Jefferies 2019 Global Healthcare Conference being held in New York.
-
Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target
5/28/2019
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced the full enrollment of cohort 2 for previously treated non-small cell lung cancer patients with HER2 exon 20 insertion mutations.
-
Spectrum Pharmaceuticals to Present Corporate Update at the 20th Annual B. Riley FBR Investor Conference on May 23rd
5/16/2019
Spectrum Pharmaceuticals announced that an overview of the company's business strategy and development-stage programs will be given at the 20th Annual B. Riley FBR Investor Conference being held in Beverly Hills, CA.
-
Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets
5/9/2019
Spectrum Pharmaceuticals, Inc. announced the closure of an asset purchase and license agreement with ImmunGene, Inc., a privately held biotechnology company.
-
Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update
5/9/2019
Spectrum Pharmaceuticals, Inc. announced financial results for the three-month period ended March 31, 2019.
-
Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call
5/2/2019
Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the first quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on Thursday, May 9, 2019 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
-
Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)
3/15/2019
Spectrum Pharmaceuticals, Inc. announced that due to the U.S. Food and Drug Administration’s request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics License Application.
-
Spectrum Pharmaceuticals to Present Corporate Update at the Oppenheimer 29th Annual Healthcare Conference on March 20
3/13/2019
Spectrum Pharmaceuticals announced that an overview of the company's business strategy and development-stage programs will be given at the Oppenheimer 29th Annual Healthcare Conference being held in New York.
-
Spectrum Pharmaceuticals Announces the Completion of the Sale of its Marketed Portfolio
3/1/2019
Spectrum Pharmaceuticals, Inc. completed the sale of its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C., a step-down subsidiary of Aurobindo Pharma Limited, India.